U.S. markets closed

Codexis, Inc. (CDXS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.94+0.08 (+0.37%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close21.86
Open22.13
Bid21.97 x 800
Ask22.00 x 1100
Day's Range21.71 - 22.50
52 Week Range10.31 - 29.56
Volume262,821
Avg. Volume522,492
Market Cap1.415B
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.42
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder
    GlobeNewswire

    Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder

    REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, today announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for the research and development of an additional gene therapy for a lysosomal storage disorder bringing the total number of programs under the agreement to four. Under the terms of the original March 2020 agreem

  • 10 Best Cheap Tech Stocks to Buy According to Cathie Wood
    Insider Monkey

    10 Best Cheap Tech Stocks to Buy According to Cathie Wood

    In this article we discuss the 10 best tech stocks to buy according to Cathie Wood. If you want to read our detailed analysis of Wood’s history, and hedge fund performance, go directly to the 5 Best Cheap Tech Stocks to Buy According to Cathie Wood. Catherine Wood, the legendary investor who runs ARK Investment […]

  • Codexis to Participate in Upcoming Virtual Healthcare Conferences
    GlobeNewswire

    Codexis to Participate in Upcoming Virtual Healthcare Conferences

    REDWOOD CITY, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Codexis, inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in three upcoming virtual investment conferences. The Jefferies Virtual Healthcare Conference – June 1, 2021 at 4:30 p.m. ET a live webcast of the fireside chat presentation will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com. A replay of the webcast will be archived for 30 days following the event.The Craig-Hallum Institutional Investor Conference – June 2, 2021, management will attend and host 1x1 investor meetings.The Piper Sandler SynBio Day – June 23, 2021, management will participate in a panel discussion. About CodexisCodexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company’s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit www.codexis.com. Forward-Looking StatementsTo the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause Codexis’ future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Codexis undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Codexis’ business in general, please refer to Codexis’ prospectus supplement to be filed with the Securities and Exchange Commission (“SEC”), including the documents incorporated by reference therein, which include Codexis’ Annual Report on Form 10-K filed with the SEC on March 1, 2021, Codexis’ Quarterly Report on Form 10-Q filed with the SEC on May 7, 2021, and Codexis’ other periodic reports filed with the SEC. Investor Relations Contact:Argot PartnersStephanie Marks/Carrie McKim(212) 600-1902Codexis@argotpartners.com